@morethanmyweight's post-surgery GLP-1 claims checked

What does this duet video claim?

Yelena (@morethanmyweight) responds to another creator's content about using Zepbound (tirzepatide) after weight loss surgery. She's 16 years post-VSG (vertical sleeve gastrectomy) and discusses her experience with GLP-1 medications following bariatric surgery.

The video touches on using tirzepatide as a weight management tool years after initial bariatric procedures. Yelena appears to advocate for GLP-1 receptor agonists as a viable option for post-surgery patients who may experience weight regain.

What does the research say about GLP-1s after bariatric surgery?

This is actually an emerging area with limited but promising data. The STEP-HW trial (Rubino et al., Lancet, 2022) specifically studied semaglutide in post-bariatric surgery patients who had regained weight.

Participants who were at least 18 months post-surgery and had regained weight lost an additional 9.6% of body weight with 2.4mg semaglutide versus 3.2% with placebo over 68 weeks. That's meaningful but not as dramatic as the 15-17% losses seen in surgery-naive patients.

The mechanism makes sense. Bariatric surgery works partly by affecting gut hormones including GLP-1. Adding exogenous GLP-1 receptor agonists can restore some of that hormonal effect when natural production wanes over time.

What are the specific considerations for this population?

Post-bariatric patients face unique challenges that Yelena's experience likely reflects. Weight regain affects 20-30% of sleeve gastrectomy patients within 5-10 years, according to longitudinal studies tracking surgical outcomes.

The STEP-HW data showed GLP-1 medications work differently in this group. The 9.6% additional weight loss is substantial but lower than the 14.9% seen in the main STEP 1 trial with treatment-naive patients.

Timing matters too. The study enrolled patients who were 18+ months post-surgery with documented weight regain. Using GLP-1s immediately after surgery hasn't been well-studied and could theoretically interfere with the natural hormonal changes that make bariatric surgery effective.

Where does Yelena get it right and wrong?

Yelena's advocacy for post-surgery GLP-1 use matches emerging clinical evidence. The STEP-HW trial supports exactly what she's describing: using these medications as a tool for patients who've had surgery but are struggling with weight regain years later.

However, she doesn't mention the reduced efficacy compared to surgery-naive patients. That 9.6% additional loss is meaningful but represents about half the effect size seen in people who haven't had bariatric procedures.

Her framing of this as a reasonable medical option is accurate. The combination approach (prior surgery plus GLP-1 medication) is becoming more accepted as bariatric medicine moves away from a "one and done" surgical mentality.

What should post-bariatric patients actually know?

The data supports GLP-1 medications as a legitimate option for weight regain after bariatric surgery, but expectations should be calibrated. You're looking at roughly 10% additional weight loss, not the 15-17% seen in surgical studies.

Insurance coverage remains complicated. Many plans that cover bariatric surgery don't automatically cover GLP-1 medications for post-surgical weight regain, despite the STEP-HW evidence.

The safety profile appears similar to other populations, but post-bariatric patients may be more sensitive to GI side effects given their altered anatomy. Starting doses and titration schedules often need modification.